Snell & Wilmer Advises Clywedog Therapeutics in Proposed Merger with Barinthus Biotherapeutics

SAN DIEGO – Snell & Wilmer represented Clywedog Therapeutics, Inc., a private biotechnology company advancing novel therapies in metabolic and autoimmune diseases, in its proposed merger with Barinthus Biotherapeutics plc (NASDAQ: BRNS), an immunology and inflammation company focused on promoting immune tolerance. The all-stock transaction will create a combined company advancing a portfolio of clinical-stage candidates for Type 1 and Type 2 diabetes as well as celiac disease.

The combined company, which will operate under the name Clywedog Therapeutics, Inc., is expected to trade on NASDAQ under the ticker symbol “CLYD.” Four key value-driving clinical milestones are anticipated within 18 months, with an estimated cash runway extending through 2027. The transaction is projected to close in the first half of 2026 and will be supported by existing investors as well as additional investments from OrbiMed and Torrey Pines Investment LLC.

“We believe that the combination of Barinthus Bio and Clywedog will create immediate value and long-term upside for all stakeholders by diversifying our pipeline and increasing the number of meaningful clinical milestones. The combined team will bring a deep scientific understanding of metabolic and autoimmune spaces together with strong clinical development experience, positioning us well to execute for patients and shareholders,” said Bill Enright, Chief Executive Officer of Barinthus Bio, in a recent press release.

Bardia Moayedi led the diverse Snell & Wilmer team advising Clywedog Therapeutics on the merger, with support from Sarah Hibbard, Monique Torres, Christopher L. Tinen, Caitlin M. Murphey, Jason A. Gersting, Eli W. Mansour, Monica Bell, Bahar A. Schippel, P.C., William Kastin, P.C., Greg Gautam, Amberlee Lapointe, Brett W. Johnson, P.C., T. Troy Galan, Clint S. Engleson, and Emily Statham.

Snell & Wilmer’s mergers and acquisitions attorneys are well-versed in providing strategic, innovative legal and business services for complicated corporate transactions. They have extensive experience with transactions in a variety of industries, including highly regulated industries where the intersection of business and government requires a particularly strategic and risk-sensitive approach. Their experience, coupled with deep industry knowledge, allows them to provide thoughtful, innovative, and comprehensive solutions for all their clients. Snell & Wilmer’s clients include sellers, buyers, investors, banks and bankers, venture capital firms, private equity firms, institutional lenders, independent directors and committees, management groups, creditors, and creditor committees.